Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WPTE 4.15 World Poker Tour(R) to Host Booth for First Time at Gaming Life Expo
WPT to Promote GSN and New Tour Stops; Hold Autograph Signings with New Hosts and WPT Boot Camp Instructors
Jul 3, 2007 9:00:00 AM
Copyright Business Wire 2007
LOS ANGELES--(BUSINESS WIRE)--
For the first time ever, the World Poker Tour(R) (WPT) will host a booth at The Rio All-Suite Hotel & Casino's Gaming Life Expo (GLE), a gaming-themed consumer trade show featuring the latest men's lifestyle and gaming products. Attendees are encouraged to visit and take photos in the WPT booth, which replicates the final table set where over 70 WPT Poker-Made Millionaires(TM) have been crowned, nearly $300 million in prize money has been awarded, and over five years of poker history has been made.
Over the four-day expo, which attracts over 100 companies and 100,000 attendees, WPT will promote a variety of new offerings. WPT will educate consumers on the move to its new network home--GSN, The Network for Games--where WPT will begin airing in early 2008 as part of the network's Monday night casino lineup. WPT will also highlight its new Season VI tour stops at the Beau Rivage in Biloxi, Miss., Casino Barcelona in Spain, and Turks & Caicos Club Med in the Caribbean.
Additionally, WPT will introduce its new Season VI hosts, Layla Kayleigh and Kimberly Lansing, and host appearances for autograph sessions throughout the event, including top pros and WPT Boot Camp(TM) instructors. A schedule of appearances is below:
July 5th Noon - 1:00pm Clonie Gowen
2:00pm - 3:00pm Tom McEvoy
3:00pm - 4:00pm Vanessa Rousso & Chad Brown
4:00pm - 5:00pm Lyle Berman
July 6th 11:00am - 4:00pm Layla Kayleigh (WPT Hostess)
1:00pm - 2:00pm Mark Seif
3:00pm - 4:00pm Antonio Esfandiari, Jennifer Tilly & Phil
Laak
4:00pm - 5:00pm Kathy Liebert
July 7th 1:00pm - 2:00pm TJ Cloutier
2:00pm - 3:00pm Mike Sexton (WPT Commentator)
3:00pm - 4:00pm Jill Spaulding
July 8th 11:00am - 4:00pm Kimberly Lansing (WPT Live Updates
Commentator)
11:00am - Noon Antonio Esfandiari
Noon - 1:00pm Linda Johnson & Jan Fisher
3:30pm - 4:30pm Gavin Smith
Celebrating its third annual event, GLE has named its 2007 event "The Gaming Life Expo - Girls, Games, and Gear" to reflect its expansion to a men's lifestyle theme. The event will be held from 11:00am to 6:00pm PT in the Rio Pavilion in Las Vegas, Thursday, July 5th through Sunday, July 8th. WPT's booth # is 511.
Season V currently airs every Wednesday night on the Travel Channel at 9PM Eastern/Pacific. Visit www.worldpokertour.com for the most up-to-date information and tournament schedule.
About WPTE
WPT Enterprises, Inc. (Nasdaq:WPTE) is a company engaged in the creation of internationally branded entertainment and consumer products driven by the development, production, and marketing of televised programming based on gaming themes. WPTE is the creator of the World Poker Tour(R), a television show based on a series of high-stakes poker tournaments that airs on the Travel Channel in the United States and is scheduled to begin broadcasting on GSN in early 2008. WPT is licensed for broadcast globally. WPTE also offers real-money online gaming on its website, www.worldpokertour.com, which prohibits wagers from players in the U.S. and certain other restricted territories. WPTE currently licenses its brand to companies in the business of poker equipment and instruction, apparel, publishing, electronic and wireless entertainment, DVD/home entertainment, casino games, and giftware. The company is also engaged in the sale of corporate sponsorships. For show information, tools for improving poker play, and other WPT news, fans may log on to www.worldpokertour.com. WPTE is a majority-owned subsidiary of Lakes Entertainment, Inc. (Nasdaq:LACO). Photos and media information can be found online at: www.worldpokertour.com/media.
WPTEG
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by WPT Enterprises, Inc.) contains statements that are forward-looking, such as statements relating to the expansion of WPTE's brand licensing, the development of new television and film projects, the development of WPTE corporate sponsors and other business development activities, as well as statements regarding other capital spending, financing sources and the effects of competition. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of WPTE. These risks and uncertainties include, but are not limited to, WPTE's significant dependence on the Travel Channel as a current source of revenue and GSN as a future source of revenue, and the risk that GSN will not exercise its options to air season of the WPT series beyond Season VI; difficulty of predicting the growth of our online gaming business, which is a relatively new industry with an increasing number of market entrants; reliance on the efforts of CryptoLogic to develop and maintain the online gaming website in compliance with WPTE's business model and applicable gaming laws; the potential that our television programming will fail to maintain a sufficient audience; the risk that competitors with greater financial resources or marketplace presence might develop television programming that would directly compete with WPTE's television programming; the risk that WPTE may not be able to protect its entertainment concepts, current and future brands and other intellectual property rights; risks associated with future expansion into new or complementary businesses; the termination or impairment of WPTE's relationships with key licensing and strategic partners; and WPTE's dependence on its senior management team. For more information, review WPTE's filings with the Securities and Exchange Commission.
Source: WPT Enterprises, Inc.
----------------------------------------------
WPT Enterprises
Inc.
Lyndsay LaGree
323-330-9876
llagree@worldpokertour.com
VRAZ 6.75 Veraz Networks, Inc. to Report Second Quarter Financial Results on Monday, August 6, 2007
Jul 3, 2007 9:00:00 AM
Copyright Business Wire 2007
SAN JOSE, Calif.--(BUSINESS WIRE)--
Veraz Networks, Inc. (NASDAQ:VRAZ) today announced that it will release financial results for the second quarter ended June 30, 2007 shortly after the close of market on Monday, August 6, 2007. Veraz will host a conference call and live webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) that day to discuss the results.
For parties in the United States and Canada, call 800-240-7305 to access the conference call. International parties can access the call at 303-262-2139.
Veraz will offer a live webcast of the conference call, which will also include forward-looking information. The webcast will be accessible from the "Investor Relations" section of the Veraz website (www.veraznetworks.com). The webcast will be archived for a period of 30 days. A telephonic replay of the conference call will also be available two hours after the call and will run for two days. To hear the replay, parties in the United States and Canada should call 800-405-2236 and enter passcode 11093088#. International parties should call 303-590-3000 and enter passcode 11093088#. In addition, Veraz's press release will be distributed via Business Wire and posted on the Veraz website before the conference call begins.
About Veraz
Veraz is a leading global provider of Internet Protocol, or IP, softswitches, media gateways and digital compression products to established and emerging wireline, wireless and broadband service providers. Service providers use Veraz products to transport, convert and manage voice traffic over legacy and IP networks, while enabling voice over IP, or VoIP, and other multimedia communications services. Veraz IP products, which consist of the company's innovative ControlSwitch softswitch solution and I-Gate 4000 family of media gateway products, enable service providers to deploy IP networks and efficiently migrate from their legacy circuit-switched networks to IP networks. Additional information about Veraz Networks (NASDAQ:VRAZ) is available at www.veraznetworks.com.
VRAZ-IR
Source: Veraz Networks, Inc.
----------------------------------------------
Investor Relations:
The Blueshirt Group
Cynthia Hiponia
415-217-4966
cynthia@blueshirtgroup.com
or
Press:
Veraz Networks
Ed Camarena
408-750-9424
edc@veraznet.com
or
PR@vantage
Ilene Adler
415-984-1970 ext. 102
iadler@pr-vantage.com
EPIX 5.43 EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Jul 3, 2007 9:00:00 AM
Copyright Business Wire 2007
LEXINGTON, Mass.--(BUSINESS WIRE)--
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX, is scheduled to present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Tuesday, July 10, 2007 at 1:30 p.m. (EDT) at the Mandarin Oriental Hotel in New York, NY.
The presentation will be webcast live and can be accessed on the EPIX website, www.epixpharma.com, in the investor relations section. A replay will be available approximately twenty-four hours after the presentation and will be archived on the company's website for two weeks.
About EPIX
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in development for conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, PRX-03140 which is in a Phase 2a clinical trial in Alzheimer's disease, PRX-00023 which is in a Phase 2b clinical trial in major depressive disorder, and PRX-07034, which recently completed a Phase 1b trial and is in clinical development for the treatment of obesity and cognitive impairment. The company also has a blood-pool imaging agent (Vasovist(TM)) approved in 32 countries and marketed in Europe. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics, and Bayer Schering Pharma AG, Germany. For more information, please visit the company's website at www.epixpharma.com.
This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q.
Source: EPIX Pharmaceuticals, Inc.
----------------------------------------------
EPIX
Kim C. Drapkin
781-761-7602
Chief Financial Officer
or
Pure Communications
Stacey Fisher
305-335-9577
gmorning folks!
morning birdies!
i think the only thing diff will be that the daily list will come out early.
ty!! whew, glad to be back..lol ;)
CDE 3.68 Coeur d'Alene Mines, Bolnisi and Palmarejo Provide Transaction Update
Coeur Completes Due Diligence Companies Committed to Closing Transaction in Fourth Quarter of 2007
Jul 3, 2007 8:50:00 AM
Copyright Business Wire 2007
COEUR D'ALENE, Idaho & SYDNEY, Australia & LONGUEUIL, Quebec--(BUSINESS WIRE)--
Coeur d'Alene Mines Corporation (NYSE:CDE) (TSX:CDM), Bolnisi Gold NL (ASX:BSG) and Palmarejo Silver and Gold Corporation (TSX VENTURE:PJO) today announced that Coeur has completed its due diligence under the terms of the Merger Implementation Agreement with Bolnisi and that the companies expect to complete the transaction in the fourth quarter of 2007.
The Joint Operating Committee has completed its work and a Project Development Committee responsible for daily management of the mine's construction consisting of professional staff from Coeur, Bolnisi and Palmarejo has been established. The companies have agreed to appoint an interim project manager to be a senior Coeur executive with substantial development and operational expertise.
While the initial focus will be to develop the Rosario deposit using open pit mining methods, the Project Development Committee will complete a pre-feasibility study by the end of August, which will include a combined open-pit and underground mine development scenario.
Based on a recently-completed scoping study and optimization work for this combined open-pit and underground mine development, the total estimated capital costs to bring the Palmarejo Project into production, including pre-stripping, underground development, mining fleet, power line, ongoing permitting, owner's costs and contingency, will be approximately US$200 million and initial production from open pit mining is expected in the fourth quarter of 2008.
"We are pleased to have completed the due diligence process, and continue to believe that this transaction is in the best interests of Coeur's shareholders," said Dennis E. Wheeler, Coeur's Chairman, President and Chief Executive Officer. "With this transaction, the companies are establishing the new Coeur as the clear leader in the silver mining industry with the addition of this world-class silver/gold asset located in Mexico. In addition, we believe the combined company's balance sheet will sufficiently fund all three of our major development projects over the next two years -- San Bartolome, Kensington, and Palmarejo -- without a need to further access the capital markets."
Norman A. Seckold, Chairman of Bolnisi and Palmarejo, said, "We continue to be very excited about this transaction, as it provides our shareholders with the opportunity to participate in the upside potential of what we believe will be the world's premier silver company. By leveraging Coeur's expertise in underground and open cut project development, we expect to realize the full value of the Palmarejo Project."
The companies expect to begin mailing information to Coeur, Bolnisi, and Palmarejo shareholders in September. All three companies' shareholder meetings are expected to be held in October. Assuming timely completion of the required regulatory processes and receipt of the required shareholder and court approvals, the companies expect the transaction to be completed in the fourth quarter of 2007.
About Coeur d'Alene Mines
Coeur d'Alene Mines Corporation is one of the world's leading primary silver producers and a growing gold producer. The company has mining interests in Alaska, Argentina, Australia, Bolivia, Chile, Nevada, and Tanzania.
About Bolnisi
Bolnisi Gold NL is an Australia-based company engaged in mining and exploration for gold and minerals. The Company's activities are all Mexican precious metals operations with an existing portfolio of projects, which include the Palmarejo Silver-Gold project (including Trogan), Chihuahua; the Yecora Gold-Silver project, Sonora, and the El Realito Gold-Silver project, Chihuahua.
About Palmarejo
Palmarejo Silver And Gold Corporation is a silver/gold exploration company listed on the TSX Venture Exchange under the symbol "PJO." Palmarejo's principal activity is to explore and develop gold and silver properties located in the Temoris District of Chihuahua, Mexico within the Sierra Madre Occidental mountain range.
Cautionary Statement
This press release contains forward-looking statements within the meaning of securities legislation in the United States and Canada, including statements regarding the terms and conditions of the proposed transaction and anticipated operating results. Such statements are subject to numerous assumptions and uncertainties, many of which are outside the control of Coeur or Palmarejo, as the case may be. Operating, exploration and financial data, and other statements in this press release are based on information that Coeur or Palmarejo, as the case may be, believes is reasonable, but involve significant uncertainties affecting the business of Coeur or Palmarejo, as the case may be, including, but not limited to, future gold and silver prices, costs, ore grades, estimation of gold and silver reserves, mining and processing conditions, construction schedules, currency exchange rates, and the completion and/or updating of mining feasibility studies, changes that could result from future acquisitions of new mining properties or businesses, the risks and hazards inherent in the mining business (including environmental hazards, industrial accidents, weather or geologically related conditions), regulatory and permitting matters, risks inherent in the ownership and operation of, or investment in, mining properties or businesses in foreign countries, as well as other uncertainties and risk factors set out in filings made from time to time with the SEC and the Ontario Securities Commission, including, without limitation, Coeur's reports on Form 10-K and Form 10-Q and Palmarejo's Annual Information Form. Additionally, there are risks that the parties will not proceed with the proposed transaction, that the ultimate terms of the proposed transaction will differ from those that currently are contemplated, and that the proposed transaction will be not be successfully completed for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities). Actual results, developments and timetables could vary significantly from the estimates presented. Readers are cautioned not to put undue reliance on forward-looking statements. Coeur and Palmarejo disclaim any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, Coeur and Palmarejo undertake no obligation to comment on analyses, expectations or statements made by third parties in respect of Coeur and Palmarejo, their financial or operating results or their securities or the proposed transaction.
Additional Information
The proxy statement that Coeur plans to file with the United States Securities and Exchange Commission ("SEC") and Canadian securities regulators and mail to its shareholders will contain information about Coeur, Bolnisi, Palmarejo, the Palmarejo Project, the proposed transaction and related matters. Shareholders are urged to read the proxy statement carefully when it is available, as it will contain important information that shareholders should consider before making a decision about the proposed transaction. In addition to receiving the proxy statement from Coeur by mail, shareholders will also be able to obtain the proxy statement, as well as other filings containing information about Coeur, without charge, from the SEC's website (www.sec.gov) and the Canadian securities regulators' website (www.sedar.com) or, without charge, from Coeur. This announcement is neither a solicitation of a proxy, an offer to purchase, nor a solicitation of an offer to sell shares of Coeur. Coeur and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Coeur's shareholders with respect to the proposed transaction. Information regarding any interests that Coeur's executive officers and directors may have in the proposed transaction will be set forth in the proxy statement. The Coeur shares to be issued in the proposed transaction have not been and will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Coeur intends to issue such Coeur shares pursuant to the exemption from registration set forth in Section 3(a)(10) of the Securities Act.
Copies of the merger implementation agreements and certain related documents will be filed with the SEC and Canadian securities regulators and will be available at the SEC's website at www.sec.gov and at the Canadian securities regulators' website at www.sedar.com.
Source: Coeur d'Alene Mines Corporation
----------------------------------------------
Coeur
Tony Ebersole
208-771-0150
Director - Investor Relations
or
Mitchell J. Krebs
888-545-1138
Senior Vice President - Corporate Development
or
Matthew Sherman / Jennifer Schaefer
Joele Frank
Wilkinson Brimmer Katcher
212-355-4449
or
Bolnisi
Norman Seckold
011 (61 2) 9247 5300
Chairman
or
Palmarejo
James Crombie
450-677-2253
President & CEO
ORBT 8.83 Orbit International Corp. Appoints Robert J. Mitzman and Sohail Malad to Its Board of Directors
Jul 3, 2007 8:45:00 AM
Copyright Business Wire 2007
HAUPPAUGE, N.Y.--(BUSINESS WIRE)--
Orbit International Corp. (NASDAQ: ORBT), an electronics manufacturer and software solution provider, today announced that Robert J. Mitzman and Sohail Malad have joined its Board of Directors, filling the vacancy left by the June 7, 2007 resignation of H. William Coogan Jr. With the appointment of Messrs. Mitzman and Malad, Orbit is again in compliance with Nasdaq's listing requirement of having a majority of independent board members.
Mr. Mitzman is the President and Chief Executive Officer of Quick International Courier ("Quick"), a provider of worldwide customized high-priority transportation services including warehousing, logistics and fulfillment services with offices in nine U.S. cities as well as London and Singapore. Quick has 600 full-time employees, 5000 service partners worldwide and conducts business on six different continents. Quick has been named as one of the top 200 privately held companies in Crain's New York Business Magazine for the past five years.
Mr. Malad is a founder and partner of Monarch Activist Partners LP ("Monarch") based in San Diego, CA, which currently own 8.9% of the outstanding shares of Orbit. Prior to founding Monarch, Mr. Malad was a consultant with the Los Angeles office of the Boston Consulting Group. Mr. Malad received his B.S. from the University of Southern California and his MBA from the Wharton School of the University of Pennsylvania.
Dennis Sunshine, President and Chief Executive Officer noted, "Messrs. Mitzman and Malad complement our Board by bringing both operating and financial expertise. We look forward to working closely with both of them and we believe that their diverse experience will help us as we pursue strategic acquisitions to complement our internal growth and enhance shareholder value."
Orbit International Corp., through its Electronics Group, is involved in the manufacture of customized electronic components and subsystems for military and nonmilitary government applications through its production facilities in Hauppauge, New York and Quakertown, Pennsylvania. Its Power Group, through its Behlman Electronics, Inc. subsidiary, manufactures and sells high quality commercial power units, AC power sources, frequency converters, uninterruptible power supplies and associated analytical equipment. The Behlman military division designs, manufactures and sells power units and electronic products for measurement and display. For a more detailed discussion of the risks inherent in the Company's business, the reader is referred to the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 and its registration statement on Form S-3 containing a final prospectus dated January 11, 2006.
This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual future results of the Company to be materially different from such forward looking statements. Factors that might result in such differences include, without limitation, the current economic climate and military conflicts, variable market conditions and changing needs of its customers. The forward-looking statements contained in this press release speak only as of the date hereof. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission.
Source: Orbit International Corp.
----------------------------------------------
Orbit International Corp.
Mitchell Binder
631-435-8300
Vice President-Finance
OR
Investor Relations Counsel:
The Equity Group Inc.
Linda Latman
212-836-9609
Lena Cati
212-836-9611
AOB 9.40 American Oriental Bioengineering, Inc. Announces Full Exercise of Over- Allotment Option and Closing of Follow-on Offering
Jul 3, 2007 8:30:00 AM
NEW YORK, July 3 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) announced today that the underwriters of the Company's recently announced follow-on public offering have exercised their option in full to purchase an additional 1,275,000 shares of the Company's common stock to cover over-allotments. In total, including the over-allotment shares, the Company will have sold 9,275,000 shares of the Company's common stock at $8.50 per share, after underwriting discounts and commissions, resulting in net proceeds of approximately $74.1 million, which includes approximately $10.2 million in net proceeds from the exercise of the over- allotment option. In addition, Tony Liu, the Company's Chairman, Chief Executive Officer and co-founder, will sell 500,000 shares in the offering. The closing of the offering, including the over-allotment shares, is expected to occur on July 3, 2007, subject to the satisfaction of customary closing conditions.
Piper Jaffray & Co. is acting as sole book-running manager for the offering and CIBC World Markets, Lazard Capital Markets, Jefferies & Company and Brean Murray, Carret & Co. are co-managers of the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on June 27, 2007. Information about this offering is available in the prospectus supplement and the accompanying prospectus filed by the Company with the Securities and Exchange Commission.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a leading, fully integrated, plant-based pharmaceutical and plant-based nutraceutical company dedicated to improving health through the development, manufacture and commercialization of modernized plant-based products in China.
SOURCE American Oriental Bioengineering, Inc.
----------------------------------------------
Wilfred Chow of SVP Finance
+1-212-786-7568; or Bill Zima and Ashley Ammon MacFarlane of Integrated Corporate Relations
Inc.
+1-203-682-8200
ATRC 8.56 AtriCure to Present at C. E. Unterberg, Towbin Emerging Growth Opportunities Conference
Jul 3, 2007 8:30:00 AM
WEST CHESTER, Ohio, July 3 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company focused on developing, manufacturing and selling innovative surgical devices, announced today that David J. Drachman, President and Chief Executive Officer, is scheduled to present at the C. E. Unterberg, Towbin Emerging Growth Opportunities Conference at the Mandarin Oriental Hotel in New York on Wednesday, July 11th, at 2:30 p.m. ET.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft and cardiac tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation "AF", a rapid, irregular quivering of the upper chambers of the heart. AF affects more than 2.5 million people in the U.S. and predisposes them to a five fold increased risk of stroke.
The FDA has cleared the AtriCure bipolar ablation system and the Isolator Synergy(TM) Bipolar Ablation System for the ablation, or destruction, of soft tissues in general and non-cardiac related surgical procedures but to date has not cleared or approved the systems for cardiac use or for the treatment of AF. The FDA has cleared the AtriCure Isolator(TM) Transpolar(TM) Pen for the ablation of cardiac tissue and the evaluation of cardiac arrhythmias, but the Isolator(TM) Transpolar(TM) Pen has not been approved for the treatment of AF.
Contacts:
AtriCure, Inc.
Julie A. Piton
Vice President and Chief Financial Officer
(513) 755-4561
jpiton@atricure.com
SOURCE AtriCure, Inc.
----------------------------------------------
Julie A. Piton
Vice President and Chief Financial Officer of AtriCure
Inc.
+1-513-755-4561
jpiton@atricure.com
OCCX 1.04 OccuLogix Enters Into Discussions for Private Placement of Common Stock to Private Equity Group
Jul 3, 2007 8:30:00 AM
BOSTON, MASSACHUSETTS -- (MARKETWIRE) -- 07/03/07 -- OccuLogix, Inc. (NASDAQ: OCCX)(TSX: OC) today announced that it has entered into discussions with JEGC OCC Corp. ("JEGC") for the private placement of approximately $30 million of common stock at a price based upon the average trading price of OccuLogix' common stock at the time of purchase, subject to regulatory approval and to a minimum price of US$1.05 per share.
JEGC is owned by Jefferson EquiCorp Ltd., a private equity firm controlled by David Folk, Managing General Partner of Jefferson Partners, and by Greybrook Corporation, a private equity firm controlled by Elias Vamvakas, Chairman and Chief Executive Officer of OccuLogix.
On May 30, 2007, TLC Vision Corporation (TSX: TLC)(NASDAQ: TLCV) and JEGC announced that JEGC had agreed to purchase TLC Vision's ownership stake in OccuLogix, subject to certain minimum prices and regulatory limitations and further subject to JEGC obtaining satisfactory financing and other customary closing conditions. It is anticipated that if both transactions are completed, JEGC will gain a control position in OccuLogix.
The securities to be offered in this private placement have not been registered under the Securities Act of 1933, as amended (the "Act") or any state securities laws or qualified under any Canadian provincial or territorial securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Act and applicable state securities laws or in Canada absent a valid prospectus, or an applicable exemption from the prospectus requirements, under applicable provincial and territorial securities laws.
About Greybrook Corporation
Founded in 1999, Greybrook (www.greybrook.com) is a private equity firm that provides capital to private and public companies, helping them to grow to the next level and maximize their value potential.
About Jefferson Partners
Jefferson Partners (www.jefferson.com) is a technology oriented venture capital firm focused on financing and building innovative world class companies.
About OccuLogix, Inc.
OccuLogix (www.occulogix.com) is a healthcare company focused on ophthalmic devices for the diagnosis and treatment of age-related eye diseases. OccuLogix is currently focused in the areas of: Dry AMD through its RHEO(TM) System (www.rheo.com); Glaucoma through its SOLX� 790 Laser and SOLX� Gold Shunt (www.solx.com); and Dry Eye Disease through the company's subsidiary, OcuSense, Inc. (www.ocusense.com).
Forward-Looking Statements
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities, including our Registration Statement on Form S-1. We do not undertake to update any forward-looking statements.
Contacts:
OccuLogix, Inc.
Stephen Kilmer
VP, Investor & Public Affairs
(905) 602-0887 ext. 3904
Email: stephen.kilmer@occulogix.com
Website: www.occulogix.com
ADSX 1.34 Scott R. Silverman Resigns as Chairman of Applied Digital's Board of Directors to Place Added Focus on VeriChip Corporation
CEO Michael E. Krawitz Assumes Mr. Silverman's Place on Applied Digital's Board; Current Board Member Daniel E. Penni Becomes New Chairman
Jul 3, 2007 8:30:00 AM
Copyright Business Wire 2007
DELRAY BEACH, Fla.--(BUSINESS WIRE)--
Applied Digital (NASDAQ:ADSX), a leading provider of identification and security technology, today announced Scott R. Silverman has resigned as Chairman of the Company's board of directors. Michael E. Krawitz, Applied Digital's Chief Executive Officer, has assumed Mr. Silverman's place on the Company's board, and Daniel E. Penni, an existing Applied Digital board member, has become Chairman. Mr. Silverman is Chairman and CEO of VeriChip Corporation, which is a majority-owned subsidiary of Applied Digital.
Mr. Silverman stated, "After several years at the helm of Applied Digital, it is the appropriate time for me to step down from the board in order to focus all of my attention on growing VeriChip, the world's premier RFID company for people with an emphasis on healthcare. I am proud of what the board and executive management team of Applied Digital accomplished during my tenure as Chairman and believe the Company has exciting times ahead. It is clear that Michael and Dan are great leaders and will continue to move the company forward."
Mr. Penni commented, "I am honored to assume the role of Chairman at Applied Digital and look forward to a productive future. We will continue to focus on improving operations and enhancing profitability at all of our subsidiaries. Although we will miss having Scott on our board, we feel this is the right decision at the right time. By stepping down, Scott will be able to devote 100 percent of his attention to VeriChip, which is one of Applied Digital's most important assets."
About Applied Digital - "The Power of Identification Technology"
Applied Digital develops innovative identification and security products for consumer, commercial, and government sectors worldwide. The Company's unique and often proprietary products provide identification and security systems for people, animals, the food supply, government/military arena, and commercial assets. Included in this diversified product line are RFID applications, end-to-end food safety systems, GPS/Satellite communications, and telecomm and security infrastructure, positioning Applied Digital as the leader in identification technology. Applied Digital is the owner of majority positions in Digital Angel Corporation (AMEX:DOC) and VeriChip Corporation (NASDAQ:CHIP).
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
Source: Applied Digital
----------------------------------------------
Applied Digital
Delray Beach
Allison Tomek
561-805-8000
atomek@adsx.com
IGO 2.16 InterSearch Reports Preliminary Second Quarter Financial Results
Jul 3, 2007 8:30:00 AM
Copyright Business Wire 2007
SAN FRANCISCO--(BUSINESS WIRE)--
InterSearch Group, Inc. (AMEX:IGO), a leading operator of industry specific destination portals such as www.Banks.com, www.IRS.com and www.Camps.com and provider of Internet search services, today announced preliminary financial results for the second quarter ended June 30, 2007.
InterSearch Group currently expects second quarter total revenue of approximately $6.8 million to $7.0 million representing a 6% to 9% year over year growth rate. Second quarter EBITDA(1) is expected to be approximately $1.1 million - $1.2 million.
"The shortfall in our expected revenue and EBITDA was primarily the result of a one-time credit made to advertisers in connection with a new traffic source which fell short of our quality standards," said Dan O'Donnell, Chairman and Chief Executive Officer of InterSearch Group. "We maintain a stringent set of quality standards in order to ensure a high value proposition for our advertisers. Our data warehouse and extensive set of analytical tools allowed us to detect, isolate, and terminate this traffic source and proactively work with our advertisers and network partners to remedy the issue and prevent future occurrences."
"Despite this one-time credit to advertisers, our business remains very strong and traffic to our properties continues to grow. We are especially pleased with progress of Banks.com. This domain is gaining traction with users and advertisers, and is expected to become a significant revenue contributor. We will provide a full financial and operating update as well as guidance for the third quarter ended September 30, 2007, on our regularly scheduled earnings call," concluded O'Donnell.
These results are unaudited and preliminary and actual results may vary. Final results for the second quarter ended June 30, 2007 will be reported by InterSearch Group on August 14, 2007 and a conference call regarding the final results will be held on such date.
Forward Looking Statements
This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding our expected financial results for the second quarter of 2007. Forward looking statements, which are based on management's current expectations, are generally identifiable by the use of terms, such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "possible," "potential," "predicts," "projects," "should," "would" and similar expressions. Forward looking statements contained in this press release include statements regarding: guidance for second quarter 2007 with respect to revenue and EBITDA and expectations regarding growth rate for second quarter 2007. The potential risks and uncertainties that could cause actual results to differ materially from those expressed or implied herein include, among others, untimely detection and termination of traffic sources which fall short of our quality standards; unanticipated slowdown in the travel and financial verticals; uncertainties related to the acceptance by customers of our enhanced versions of www.Banks.com and www.Camps.com; unexpected diversion of advertising dollars away from the Internet; slower than anticipated growth rate of InterSearch Group's advertising base; dependence on our search providers; and market development of Internet advertising and paid search services. Further information on the factors that could affect InterSearch Group's financial results is included in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006, our quarterly reports on Form 10QSB and our Current Reports on Form 8-K. Except as required by law, we assume no responsibility to update these forward looking statements publicly, even if new information becomes available in the future.
Non-GAAP Financial Measures
InterSearch Group's management evaluates and monitors performance for InterSearch Group primarily through EBITDA. In addition, EBITDA is presented because management believes it is frequently used by securities analysts, investors and others in the evaluation of companies. EBITDA is calculated by adding income taxes, interest expense, depreciation and amortization to net earnings. EBITDA is not defined under GAAP(2) and should not be considered in isolation or as a substitute for net earnings and other consolidated earnings data prepared in accordance with GAAP or as a measure of InterSearch Group's profitability.
About InterSearch Group, Inc.
InterSearch Group is a leading operator of industry specific destination portals and provider of Internet search services through a combination of traffic aggregation and proprietary websites, such as www.Banks.com, www.IRS.com and www.Camps.com. InterSearch Group operates in the fastest growing segments of Internet commerce including paid search, direct navigation and online marketing driving high quality traffic to advertisers and providing users with quick access to pertinent products and services. Through its corporate services division, InterSearch Group also provides Internet technology related professional services to large corporations, predominantly in the Financial Services industry. InterSearch Group is headquartered in San Francisco, California at 222 Kearny Street, Suite 550, and can be reached via telephone at 415-962-9700. More information about InterSearch Group can be found at: www.InterSearch.com.
(1) EBITDA is a non-GAAP financial measure. This measure may be different from non-GAAP financial measures used by other companies. We encourage investors to review the section below entitled "Non-GAAP Financial Measures" and to review the reconciling adjustments between the GAAP and non-GAAP measures attached to this press release.
(2) Generally Accepted Accounting Principles in the United States of America.
Source: InterSearch Group, Inc.
----------------------------------------------
For InterSearch Group
Inc.
Jon Avidor
415-445-3234
Investor Relations
Jon@marketstreetpartners.com
SHOR 10.50 ShoreTel Prices Initial Public Offering
Jul 3, 2007 8:30:00 AM
Copyright Business Wire 2007
SUNNYVALE, Calif.--(BUSINESS WIRE)--
ShoreTel, Inc., a leading provider of enterprise IP telephony solutions, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock at a price to the public of $9.50 per share. In addition, ShoreTel(R) has granted the underwriters a 30-day option to purchase up to an additional 1,185,000 shares of common stock. ShoreTel's common stock will trade on the Nasdaq Global Market under the ticker "SHOR".
Lehman Brothers Inc. and J.P. Morgan Securities Inc. are acting as joint book-running managers for the offering, and Piper Jaffray & Co., JMP Securities LLC, and Wedbush Morgan Securities Inc. are acting as co-managers.
The offering is being made only by means of a prospectus, a copy of which may be obtained from the prospectus department of Lehman Brothers Inc., c/o Broadridge, 1155 Long Island Avenue, Edgewood, NY 11717 (fax: 1-631-254-7140, or e-mail at qiana.smith@broadridge.com) or from J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS Level; Brooklyn, New York 11245 (telephone: 1-866-430-0686).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Source: ShoreTel, Inc.
----------------------------------------------
The Blueshirt Group for ShoreTel
Erica Abrams
1-408-331-3615 (Investor Relations)
ir@shoretel.com
GMET 7.18 GeoMet Announces Planning for Initial 25 Development Wells at Peace River Project
Jul 3, 2007 8:30:00 AM
Copyright Business Wire 2007
HOUSTON--(BUSINESS WIRE)--
GeoMet, Inc. (NASDAQ:GMET) ("GeoMet" or the "Company") announced today the decision to move its Peace River exploration and evaluation project (the "Project") into the next phase of activity. GeoMet's wholly-owned Canadian operating subsidiary, Hudson's Hope Gas, Ltd., will immediately begin the necessary steps to drill approximately 25 wells. The Project consists of approximately 44,468 gross acres (22,334 acres, net to the Company) in the Peace River area near Hudson's Hope, British Columbia. GeoMet is the operator and owns a 50% working interest in the Project. Canada Energy Partners Inc. (TSV-X:CE) owns the remaining interest.
During the last three years, the Company has drilled or recompleted seven production test wells, one produced water disposal well and conducted gas desorption tests on all the targeted coal seams. The Company has recently completed an extensive economic evaluation based on the test well program and projected development and operating costs, which yielded attractive results.
Hudson's Hope Gas, Ltd. will begin consultations with affected communities and First Nations (Canadian indigenous populations). GeoMet will begin the design of the initial drilling plan which will include at least one produced water disposal well and the necessary project infrastructure and gas treating and sales facilities. Thereafter, GeoMet will finalize permitting and, after final approval by the Company's Board of Directors, initiate construction of drilling locations and infrastructure. Drilling would commence sometime thereafter depending upon seasonal operating restrictions and/or conditions.
About GeoMet, Inc.
GeoMet, Inc. is an independent energy company engaged in the exploration for and development and production of natural gas from coal seams ("coalbed methane" or "CBM"). Our principal operations and producing properties are located in the Cahaba Basin in Alabama and the Central Appalachian Basin in West Virginia and Virginia. We also control additional oil and gas and coalbed methane development rights, principally in Alabama, British Columbia, Colorado, Louisiana, Virginia, and West Virginia.
For more information please contact Stephen M. Smith at 713-287-2251 or ssmith@geometcbm.com or visit our website at www.geometinc.com.
Forward Looking Statements Notice
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are our estimate of the sufficiency of our existing capital sources, our ability to raise additional capital to fund cash requirements for future operations, the uncertainties involved in estimating quantities of proved oil and natural gas reserves, in prospect development and property acquisitions and in projecting future rates of production, the timing of development expenditures and drilling of wells, and the operating hazards attendant to the oil and gas business. In particular, careful consideration should be given to cautionary statements made in the various reports the GeoMet has filed with the Securities and Exchange Commission. GeoMet undertakes no duty to update or revise these forward-looking statements.
Source: GeoMet, Inc.
----------------------------------------------
GeoMet
Inc.
Houston
Stephen M. Smith
713-287-2251
ssmith@geometcbm.com
www.geotmetinc.com
ARBA 9.98 Ariba SupplyWatch Roadshow Stops in Munich
Pfizer AG to Join Ariba Category Specialists in Outlining Strategies for Strategic Sourcing and Spend Management Success During July 10 Event
Jul 3, 2007 8:30:00 AM
Copyright Business Wire 2007
SUNNYVALE, Calif.--(BUSINESS WIRE)--
Leading companies recognize that it takes more than technology to drive spend management success. On Tuesday, July 10, Pfizer AG will join Ariba, Inc. (Nasdaq:ARBA), the leading spend management solutions provider, in discussing how procurement professionals can leverage market knowledge and commodity expertise to define and execute effective sourcing and spend management strategies that deliver results. Part of the Ariba European SupplyWatch Roadshow Series, the event will be held at the Sofitel Munchen Bayerpost in Munich.
"With more than 300 category specialists and 400 sourcing professionals in key markets around the globe, Ariba has unparalleled domain knowledge and expertise that companies can leverage to effectively manage their spend," said Ulrich Pusch, Manager, Central Europe, Ariba. "Through our SupplyWatch Roadshows, procurement professionals can gain insight into the lessons we have learned from working with more than 550 companies to source over $450 million in direct and indirect goods and services across 5,000 unique categories as well as the best practices that leading companies like Pfizer are employing to identify sourcing opportunities and convert them into real savings."
The Munich event is the final stop on Ariba's European SupplyWatch Roadshow, which started out in June. During the half-day session, Denise Gerber, Head Strategic Sourcing and Supply Chain Management, Pfizer AG, will join Ariba category specialists in discussing global market dynamics and commodity trends and sharing best practices that can be readily applied across organizations of all types and sizes to lower costs and increase competitive advantage.
For more information on the Ariba event, or to register, please visit: http://www.ariba.com/company/supplywatch2007.cfm
About Ariba, Inc.
Ariba, Inc. is the leading provider of spend management solutions to help companies realize rapid and sustainable bottom line results. Successful companies around the world in every industry use Ariba Spend Management(TM) software and services. Ariba can be contacted in the U.S. at 1.650.390.1000 or at www.ariba.com.
Copyright (C) 1996 - 2007 Ariba, Inc.
Ariba, the Ariba logo, AribaLIVE and SupplyWatch are registered trademarks of Ariba, Inc. Ariba Spend Management, Ariba Spend Management. Find it. Get it. Keep it., Ariba. This is Spend Management, Ariba Solutions Delivery, Ariba Analysis, Ariba Buyer, Ariba Category Management, Ariba Category Procurement, Ariba Contract Compliance, Ariba Contracts, Ariba Contract Management, Ariba Contract Workbench, Ariba Data Enrichment, Ariba eForms, Ariba Electronic Invoice Presentment and Payment, Ariba Invoice, Ariba Sourcing, Ariba Spend Visibility, Ariba Travel and Expense, Ariba Procure-to-Pay, Ariba Workforce, Ariba Supplier Network, Ariba Supplier Connectivity, Ariba Supplier Performance Management, Ariba PunchOut, Ariba QuickSource, PO-Flip, Ariba Settlement, Ariba Spend Management Knowledge Base, Ariba Ready, Ariba Supply Lines, Ariba Supply Manager, Ariba LIVE and It's Time for Spend Management are trademarks or service marks of Ariba, Inc. Ariba Proprietary and Confidential. All rights reserved. Patents pending. All other trademarks are property of their respective owners.
Ariba Safe Harbor
Safe Harbor Statement under the Private Securities Litigation Reform Act 1995: Information and announcements in this release involve Ariba's expectations, beliefs, hopes, plans, intentions or strategies regarding the future and are forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this release are based upon information available to Ariba as of the date of the release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to Ariba's operating and financial results to differ materially from its current expectations include, but are not limited to: delays in development or shipment of new versions of Ariba's products and services; lack of market acceptance of Ariba's existing or future products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; the ability to attract and retain qualified employees; difficulties in assimilating acquired companies; long and unpredictable sales cycles and the deferrals of anticipated orders; declining economic conditions; inability to control costs; changes in the company's pricing or compensation policies; significant fluctuations in our stock price; the outcome of and costs associated with pending or potential future regulatory or legal proceedings; the impact of our acquisitions, including the disruption or loss of customer, business partner, supplier or employee relationships; and the level of costs and expenses incurred by Ariba as a result of such transactions. Factors and risks associated with its business, including a number of the factors and risks described above, are discussed in Ariba's Form 10-Q filed May 9, 2007.
Source: Ariba, Inc.
----------------------------------------------
For Ariba
Svenja Op gen Oorth
+49 89 242 038 20
svenja.opgenoorth@eloquenza.de
RITT 1.32 RiT Receives Another Major Chinese Order
Jul 3, 2007 8:01:00 AM
TEL AVIV, Israel, July 3 /PRNewswire-FirstCall/ --
- Sales in China Pass the $1M Mark
RiT Technologies (NASDAQ: RITT), the world-leading provider of intelligent infrastructure management solutions, today announced that it has received and delivered another significant order from one of China's largest corporations. The order is for a large and complex PatchView(TM) intelligent infrastructure management solution that will manage tens of thousands of ports at the company's new headquarters building. The installation will be carried out by the network's system integrator, and is scheduled to be completed during the third quarter of 2007.
This order brings the Company's sales in China to more than $1 million, a milestone that RiT has achieved in less than a year since establishing a representative office in Beijing.
"We are very proud to record this major order from China, a fast-growing market that offers us significant potential," said Mr. Doron Zinger, RiT's President and CEO. "We are equally proud to have reached the $1 million sales milestone, an accomplishment that validates the suitability of our product, sales and support capability for this vast market. Working together with our local OEM partners, we continue with aggressive efforts that target the many significant opportunities that we have identified in China."
About RiT Technologies
RiT is a leading provider of physical network infrastructure control and management solutions. Deployed in the networks of many of the world's largest carriers and enterprises, its pioneering, fast-ROI products have proven their ability to simplify service deployment and provisioning, enhance troubleshooting accuracy, reduce infrastructure maintenance costs, enhance physical layer security and enable cost-effective service qualification and verification.
RiT is a member of the RAD group, a world leader in communications solutions. For more information, please visit our website: www.rittech.com
Company contact:
Simona Green
VP Finance
+972-3-766-4249
simonag@rit.co.il
SOURCE RiT Technologies Ltd
----------------------------------------------
Company contact: Simona Green
VP Finance
+972-3-766-4249
simonag@rit.co.il
ILI 1.74 Interleukin Genetics Announces Executive Management and Board Changes
Jul 3, 2007 8:00:00 AM
WALTHAM, Mass., July 3 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (Amex: ILI) today announced that Chief Executive Officer Tim Richerson is resigning to pursue other opportunities. Mr. Richerson will formally leave Interleukin on July 31, 2007 and until that time will oversee operations of the Company's Alan James Group business and ensure an orderly transition. Thomas Curran, Interleukin's Chairman of the Board, will assume the role of Interim Chief Executive Officer while the Board of Directors conducts a search for the best candidate for the role of CEO.
"Interleukin appreciates the dedication Tim has shown during his tenure as CEO, and we wish him the best in his future endeavors," stated Mr. Curran. "Interleukin continues to make important progress to position our business to take advantage of the emerging personalized health marketplace. We are excited about 2008 and expect to have four genetic tests available for consumers in North America. In addition, we expect to launch our first genetic test internationally in 2009. With our scientific capabilities, strong marketing partner Alticor and the increasing personalization in healthcare, we are optimistic about future opportunities."
Interleukin also announced that James Weaver has been named to the Board to serve as a Series A Director. Mr. Weaver is currently Vice President of Alticor Corporate Enterprises. Additionally, the company announced that David Finkelstein, Chief Strategy Officer, has resigned his position, effective immediately.
About Interleukin Genetics
Interleukin Genetics, Inc. is focused on developing, acquiring, and commercializing personalized health products that can help individuals improve and maintain their health through preventive measures. It uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. The Company also develops and markets nutritional and OTCeutical(R) products. Interleukin has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. In addition, through its Alan James Group subsidiary which it acquired in August 2006, Interleukin sells its nutritional product brands, including Ginkoba(R), Ginsana(R), and Venastat(R) through the nation's largest food, drug and mass retailers. The Company's current development programs focus on osteoporosis and weight management genetic risk assessment tests, as well as its new proprietary OTCeuticals for distribution through Alan James Group. The Company expects that these programs will also lead to the personalized selection of nutritional products, and provide consumers and healthcare professionals with better preventive product alternatives. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, our ability to integrate acquired businesses, our ability to maintain relationships with our important customers, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006, as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10-Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
SOURCE Interleukin Genetics, Inc.
----------------------------------------------
For Interleukin Genetics: Paul Voegelin
+1-781-398-0700; Additional Contacts for Media / Investors: J.J. Rissi
+1-212-445-8224
Weber Shandwick; or Rich Tauberman
+1-201-964-2408
Financial Relations Board
PXPL .74 Pixelplus to Announce FY2007 Q1 Results on July 5, 2007
Jul 3, 2007 8:00:00 AM
SEOUL, South Korea, July 3 /PRNewswire-FirstCall/ -- Pixelplus Co., Ltd. (Nasdaq: PXPL), a leading fabless semiconductor company in Korea that designs, develops, and markets CMOS image sensors for various consumer electronics applications, will announce its results for the first quarter of 2007 on Thursday, July 5, 2007, New York time.
The Company will host a conference call at 5 p.m. on Thursday, July 5, 2007, New York time.
To obtain dial-in details for the call, please contact Taylor Rafferty at the numbers provided below.
About Pixelplus Co., Ltd.
Pixelplus is a South Korea-based developer of high-performance, high- resolution, and cost-effective CMOS image sensors for use primarily in mobile camera phones. In addition to mobile phones, Pixelplus provides CMOS image sensors and SoC solutions for use in webcams and notebook embedded cameras, toys and games, and security and surveillance system applications.
As a fabless semiconductor company, Pixelplus is focused on creating proprietary design technologies to develop CMOS image sensors with sharp, colorful and enhanced image quality, size efficiency, and low power consumption.
Contact:
Shane Y. Hong
Pixelplus Co., Ltd.
6th Floor, Gyeonggi R&DB Center
906-5 Iui-dong, Yeongtong-gu
Suwon-si, Gyeonggi-do, 443-766
Republic of Korea
+82-31-888-5300
OR
Taylor Rafferty:
London - Stewart Taylor at +44 (0) 20 7614 2900
New York - Allon Bloch at +1 212 889 4350
Seoul - Jisook Shim at +82 (0) 2 2000 5753
Tokyo - James Hawrylak at +81 (0) 3 5444 2730
Email pixelplus@taylor-rafferty.com
SOURCE Pixelplus Co., Ltd.
----------------------------------------------
Shane Y. Hong of Pixelplus Co.
Ltd.
+82-31-888-5300; In London
Stewart Taylor
+44(0)20-7614-2900; In New York
Allon Bloch
+1-212- 889-4350; In Seoul
Jisook Shim
+82(0)2-2000-5753; In Tokyo
James Hawrylak
+81(0)3-5444-2730
pixelplus@taylor-rafferty.com
all for Pixelplus Co.
Ltd.
of Taylor Rafferty
REDE 6.51 RedEnvelope, Inc. Reports Fourth Quarter and Full Year Fiscal 2007 Results
Jul 3, 2007 8:00:00 AM
SAN FRANCISCO, July 3 /PRNewswire-FirstCall/ -- RedEnvelope, Inc. (Nasdaq: REDE) today reported financial results for the fourth quarter and fiscal year ended April 1, 2007.
Net revenues for the fourth quarter of fiscal 2007 were $21.9 million, compared to $22.0 million in the fourth quarter of fiscal 2006. Net loss was $(4.3) million, or $(0.45) per diluted share, compared to a net loss of $(4.5) million, or $(0.49) per diluted share in the fourth quarter of fiscal 2006. Net loss for the fourth quarter of fiscal 2007 includes stock option expenses of $696,000 as required by SFAS No. 123(R), "Share-Based Payment," which was adopted on April 3, 2006.
For the fiscal year ended April 1, 2007, net revenues grew to $121.3 million, compared to $113.2 million recorded in fiscal year 2006. Net loss for fiscal year 2007 fell to $(3.5) million, or $(0.38) per diluted share, compared to a net loss of $(5.6) million, or $(0.62) per diluted share, in the prior year.
Fiscal 2007 Business Highlights
-- Net revenues per order grew 8.1% to approximately $85 compared to
approximately $79 in fiscal 2006
-- Approximately 1.4 million orders shipped, representing approximately 1%
fewer than in fiscal 2006
-- Gross profit per order increased 10.7% to approximately $45 compared to
approximately $40 in fiscal 2006
-- New customers grew by approximately 514,000 from the end of fiscal
2006, bringing the total customer file to approximately 3.4 million
names
Gross profit margin was approximately 49.0% in the fourth quarter of fiscal 2007, compared to 48.8% in the same period last fiscal year. For the fiscal year, gross profit margin increased to approximately 52.4% from 51.2% in fiscal 2006. The gross margin increase for the year was primarily due to higher shipping margins.
Marketing expenses in the fourth quarter of fiscal 2007 were 23.7% of net revenues, compared to 20.9% in the same period last year. For the year, marketing expenses decreased to 22.4% of net revenues, from 23.2% in fiscal 2006.
Fourth quarter fulfillment expenses decreased to 15.5% of net revenues from 15.9% in the fourth quarter of fiscal 2006. Fulfillment expenses remained flat for the year at approximately 14%.
General and administrative expenses decreased to $6.6 million in the fourth quarter of fiscal 2007 and increased to $23.1 million in fiscal 2007, from $7.3 million and $21.5 million, respectively, in the comparable periods last year. The year-over-year increase was primarily due to $2.4 million in stock option expenses as a result of the adoption of SFAS No. 123(R).
As of April 1, 2007, RedEnvelope had $13.2 million in cash and short-term investments and no debt. The Company currently expects to encounter seasonal borrowing needs as it builds holiday inventory, and has a credit facility of up to $12.5 million, subject to an inventory-based formula, available for that purpose. The Company also has a stand-by subordinated, unsecured credit arrangement for up to $2.6 million from The Integrity Brands Fund, L.P., which is managed by the Company's Executive Chairman and is a holder of approximately 8% of the Company's outstanding shares. Inventory decreased to $14.3 million at the end of fiscal 2007, compared to $19.7 million at the end of fiscal 2006. Capital expenditures for fiscal 2007 were approximately $4.0 million.
John Pound, RedEnvelope's Executive Chairman, made the following comments on the Company's results and its current position.
"As Executive Chairman, and as a large investor in RedEnvelope, I am enthusiastic about the power of the brand and the growth opportunities for the Company. This year, we are moving aggressively to demonstrate the true long-term potential of the brand. In this release I'd like to provide you with a relatively detailed update on our current situation and our future strategy.
"The negative trends that can be seen in our fourth quarter results reflect three core legacies of last year. They are: an uninspired and unfocussed creative message (as manifested in both our catalogs and our web site); an unfocussed and tired product assortment; and a shift in our marketing focus away from the critical necessity of customer acquisition. Together, these three issues meant that, in the third and fourth quarters of fiscal 2007 and year-to-date fiscal 2008, we were seeking out fewer new customers, and conversion was down among both new and existing customers. To overcome these issues during the holiday season last year, we drove achieved sales results through aggressive product discounts, which not only devalued the brand, but also further alienated our core customer.
"We currently believe the impact of these issues will be felt through the remainder of fiscal 2008. In particular, we expect that there will be a cumulative overhang from our lower customer acquisition rates that will affect the balance of this fiscal year, simply because we are drawing on a smaller and less motivated customer base relative to the Company's historical customer pool. We currently estimate that it will take two to four quarters to change direction as we rebuild the customer file. While it is difficult to quantify the impact at this time, we currently believe that for fiscal 2008, RedEnvelope's top line will be below that of fiscal 2007 just ended, and that the Company will experience negative net cash flows.
"That said, however, there now is a lot of good news at RedEnvelope as we look toward next year. We have assembled a terrific team of individuals at the top who have fresh perspectives and the right creative and analytical skills -- the critical combination of art and science -- to drive the RedEnvelope brand. Since I assumed the role of Executive Chairman about 90 days ago, we have focused on an intensive assessment of the state of the business and on developing a key set of strategies to re-invigorate the brand and drive it forward. As a result of that process, we believe we know what we need to do to drive the business effectively. Our key strategies are:
-- Elevate and focus our creative message to reconnect with our customer
and offer a unique value proposition, centered around our core brand
mission of inspiring and supporting giving;
-- Upgrade our product offering, so that it is new, fresh, aspirational,
brand appropriate, and of high quality;
-- Restructure our merchandising department to support more newness and a
better assortment of aspirational product;
-- Shift our marketing strategy so that we are once again focused on
efficient customer acquisition -- the lifeblood of any direct company
-- including great public relations and alternative marketing efforts;
and
-- More effectively drive demand through the web rather than primarily
through our catalog distribution (as is currently the case, in spite of
notionally being a web business).
"We are already making great progress towards all of these goals. In the past 90 days, we have:
-- Re-worked the brand message and creative vision, which we will present
to the consumer later this year;
-- Tightened and focused our short-term (fall and holiday) product
assortment, dropping a proliferation of challenged SKU's, while
concurrently adding some meaningful new product offerings;
-- Begun a longer-term shift in the structure of our merchandising efforts
in order to create more effective and on-brand aspirational product;
-- Tapped our customer data to develop a rigorous understanding of our
demographic and the dynamics of the business;
-- Built a baseline financial and operating plan based on a bottoms-up
analysis supported by the dynamics of our customer file;
-- Shifted our operating and technology goals for the balance of 2007 to
create a streamlined agenda that allows us to remain focused on our key
creative and marketing needs; and
-- Begun an evaluation of longer-term operating and technology needs with
an eye toward evolutionary improvements in 2008 and beyond.
"The first and most visible evidence of this program of changes will occur in September. In our first 30 days, we focused intensively on our creative message and brand strategy because these can be affected visibly and quickly in a direct business. As a result, in September, the look and feel of both our catalog and our website will change significantly. We will be once again a focused, aspirational brand. We will present ourselves as a unique lifestyle partner for our customer, offering a strong editorial brand voice that offers gift-giving as a way of celebrating, making, and memorializing life's important relationships. We will be emotional, connected, and relevant -- inspirational, funny, unexpected, and real.
"Improvements in merchandise will also begin to be visible beginning in the fall, becoming more so in our holiday offering. Due to the lead times involved in vertical merchandising and product development, product improvement will be an ongoing process that we plan to continue through fiscal 2008 and into fiscal 2009. In the fall, we will also be able to shift marketing to again focus on acquiring new customers. We currently plan to expand this effort in holiday and into fiscal 2009.
"This will be a year of investment -- in the future of the brand and the platform that we are building in the direct marketing space. We will be managing the business this year with our eyes trained on the core underlying customer and transaction metrics that ultimately drive our success. From a financial viewpoint, we will need to make investments -- in strengthened marketing, creative and merchandising effort -- to support the brand, and we currently believe that improved financial results will follow from these investments.
"While RedEnvelope has historically given guidance to the public market, we will not continue this practice during the current fiscal year. In making this decision, we do not mean to imply any reduction in our commitment to our public shareholders. Rather, given the transitional state of the business, we do not yet have the visibility to provide reliable forecasts. We want our team to be focused on the core internal leading indicators that give us immediate visibility on how our initiatives are taking hold. For the same reasons, we will also be substituting detailed press releases for our traditional quarterly conference calls for the balance of this fiscal year.
"We believe that we are building a strong platform at RedEnvelope -- a platform that can also successfully grow into a mature branded direct lifestyle business, addressing our core customer with additional sub-brands that are relevant to additional areas of her life. We are working hard to address the core challenges and opportunities of the business, and we are fortunate to have the talented and dedicated team that has coalesced at RedEnvelope, working to accomplish our goals. I am gratified to have their confidence. We all believe in the brand and the future of the Company. "
About RedEnvelope, Inc.
RedEnvelope, Inc. is a retailer dedicated to inspiring people to celebrate their relationships through giving. RedEnvelope offers an extensive collection of imaginative gifts through its webstore, http://www.RedEnvelope.com.
"RedEnvelope" is a registered trademark of RedEnvelope, Inc.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives and future operations and estimates of our financial results and capital expenditures for future periods. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. Factors that could affect future performance include, but are not limited to: any failure to obtain short-term or other financing if necessary; marketing, advertising and customer acquisition programs and related expenditures may not achieve desired results; cost-control measures may fail to yield satisfactory results; changes in key management positions and personnel; the inability to attract and retain qualified managerial, creative and technical personnel; integration of recently hired key personnel, and other managerial, technical, finance, accounting and operations personnel, and potential disruption occasioned thereby; failure of the market to accept our new or existing products and competition relating to such products; planned and ongoing fulfillment center and system upgrades and enhancements could fail to achieve desired results or cost savings or could take longer or incur greater costs than anticipated to implement; difficulties encountered in, or increased costs of, fulfillment; economic conditions and changes in consumer spending levels; any significant disruption of our operations due to network or systems failures or disruptions, power outages, regulatory actions, natural disasters or attacks; difficulties encountered in predicting consumer preferences, managing inventory levels or gaining access to popular products; increased or more effective competition from other retailers; difficulties encountered in managing our growth; increased costs for, or delays or difficulties in the receipt of, merchandise ordered by us; seasonality of the retail business; increases in shipping, advertising or marketing costs; intellectual property or other claims that may have an adverse effect on our financial results product offerings or technology; difficulties encountered in properly staffing our operations or providing satisfactory customer service; changes in government or regulatory requirements affecting e-commerce that may restrict, or increase the cost of, our operations, and other risk factors described in detail in our Report on Form 10-K for the fiscal year ended April 1, 2007, including, without limitation, those discussed under the captions, "Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which document is on file with the Securities and Exchange Commission (the "SEC") and available at the SEC's website at http://www.sec.gov. These forward-looking statements are made only as of the date of this press release, and RedEnvelope undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. The lack of any update or revision is not intended to imply continued affirmation of forward-looking statements contained herein.
Investor Contact: Andrew Greenebaum/Christine Lumpkins
ICR, Inc.
agreenebaum@icrinc.com; clumpkins@icrinc.com
(310) 954-1100
- Financial Tables Follow -
REDENVELOPE, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
Thirteen Weeks Ended
April 1 April 2
2007 % 2006 %
(In thousands, except for per share data)
Net revenues $21,897 100.0% $22,044 100.0%
Cost of sales 11,160 51.0% 11,296 51.2%
Gross profit 10,737 49.0% 10,748 48.8%
Operating expenses:
Fulfillment 3,395 15.5% 3,515 15.9%
Marketing 5,190 23.7% 4,604 20.9%
General and
administrative 6,627 30.3% 7,254 32.9%
Total operating
expenses 15,212 69.5% 15,373 69.7%
Loss from operations (4,475) -20.4% (4,625) -21.0%
Interest income, net 221 1.0% 142 0.6%
Net loss $(4,254) -19.4% $(4,483) -20.3%
Net loss per share
- basic and diluted $(0.45) $(0.49)
Weighted average shares
outstanding - basic
and diluted 9,485 9,101
Fifty-two Weeks Ended
April 1, April 2,
2007 % 2006 %
(In thousands, except for per share data)
Net revenues $121,273 100.0% $113,175 100.0%
Cost of sales 57,729 47.6% 55,279 48.8%
Gross profit 63,544 52.4% 57,896 51.2%
Operating expenses:
Fulfillment 17,050 14.1% 16,092 14.2%
Marketing 27,209 22.4% 26,284 23.2%
General and
administrative 23,142 19.1% 21,462 19.0%
Total operating
expenses 67,401 55.6% 63,838 56.4%
Loss from operations (3,857) -3.2% (5,942) -5.2%
Interest income, net 322 0.3% 320 0.2%
Net loss $(3,535) -2.9% $(5,622) -5.0%
Net loss per share
- basic and diluted $(0.38) $(0.62)
Weighted average shares
outstanding -- basic
and diluted 9,400 9,007
REDENVELOPE, INC.
BALANCE SHEETS
(Unaudited)
April 1, April 2,
2007 2006
(In thousands)
ASSETS
Current assets:
Cash and cash equivalents $13,245 $ 3,277
Short-term investments -- 6,762
Accounts receivable, net 1,050 1,054
Inventory 14,288 19,690
Prepaid catalog costs and other
current assets 2,423 2,793
Total current assets 31,006 33,576
Property and equipment, net 8,221 7,255
Other assets 184 146
Total assets $39,411 $ 40,977
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued
expenses $12,463 $ 13,829
Capital lease obligations, current 207 312
Total current liabilities 12,670 14,141
Capital lease obligations, long-term 350 136
Deferred rent 502 710
Total liabilities 13,522 14,987
Stockholders' equity:
Common stock 96 94
Additional paid-in capital 118,799 115,367
Notes receivable from stockholders (44) (44)
Accumulated deficit (92,962) (89,427)
Total stockholders' equity 25,889 25,990
Total liabilities and stockholders'
equity $39,411 $ 40,977
REDENVELOPE, INC.
STATEMENTS OF CASH FLOWS
(Unaudited)
Fifty-two Weeks Ended
April 1, April 2,
2007 2006
(In thousands)
Cash Flows From Operating Activities:
Net loss $(3,535) $(5,622)
Adjustments to reconcile net loss to
net cash provided by operating activities:
Depreciation 3,024 3,119
Stock-based compensation 2,705 503
Loss on disposal of property and equipment 2 217
Other non-cash charges (153) (29)
Changes in current assets and liabilities:
Accounts receivable, net 4 (62)
Inventory 5,402 (5,642)
Prepaid catalog and other assets 421 1,401
Accounts payable and accrued expenses (1,689) (1,222)
Net cash provided by (used in) operating
activities 6,181 (7,337)
Cash Flows From Investing Activities:
Maturities of short-term investments 11,619 61,664
Purchases of short-term of investments (4,857) (54,075)
Purchase of property and equipment (3,171) (2,367)
Net cash provided by investing activities 3,591 5,222
Cash Flows From Financing Activities:
Proceeds from issuance of stock 848 1,245
Forfeiture of restricted stock (1) --
Repurchase of restricted stock (118) --
Principal payments on capital
lease obligations (389) (660)
Payment of debt acquisition costs (144) --
Proceeds from line of credit 6,700 --
Repayment of line of credit (6,700) --
Net cash provided by financing activities 196 585
Net increase (decrease) in cash and cash
equivalents 9,968 (1,530)
Cash and cash equivalents at beginning
of period 3,277 4,807
Cash and cash equivalents at end of period $13,245 $3,277
SOURCE RedEnvelope, Inc.
----------------------------------------------
Andrew Greenebaum
agreenebaum@icrinc.com
or Christine Lumpkins
clumpkins@icrinc.com
both of ICR
Inc.
both at +1-310-954-1100
for RedEnvelope
Inc.
SNSS 3.56 Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
Jul 3, 2007 8:00:00 AM
SOUTH SAN FRANCISCO, Calif., July 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Eric Bjerkholt, Sunesis' Senior Vice President, Corporate Development and Finance, will present a company update at the C. E. Unterberg, Towbin Emerging Growth Conference on July 12, 2007 at 9:00 a.m. Eastern Time in New York, NY.
Interested parties may access the webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks until July 26, 2007.
Option Award Disclosure
The Compensation Committee of the company's Board of Directors approved an employment commencement grant to Mr. Michael Coors, Director, Quality Assurance, of a non-qualified stock option to purchase 25,000 shares of Sunesis common stock, effective June 29, 2007. These option awards were granted without shareholder approval pursuant to Nasdaq Marketplace Rule 4350 (i)(1)(A)(iv) and with the following material terms: (a) an exercise price equal to the fair market value of the company's common stock on the grant date, (b) a term of ten years, and (c) a vesting schedule providing that the option is exercisable as to one-quarter of the total grant on the first anniversary of their hire, and one-forty-eighth of the total grant each month thereafter until the grant is fully vested.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.
SOURCE Sunesis Pharmaceuticals, Inc.
----------------------------------------------
investors
Eric Bjerkholt
SVP
Corp. Development & Finance of Sunesis Pharmaceuticals
Inc
+1-650-266-3717; media
Karen L. Bergman
+1-650-575-1509
or Michelle Corral
+1-415-794-8662
both of BCC Partners
for Sunesis Pharmaceuticals
Inc.
BIOM 1.00 Biomira files investigational new drug application for PX-478, a novel inhibitor of hypoxia-inducible factor-1 alpha
Jul 3, 2007 8:00:00 AM
EDMONTON, July 3 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for PX-478. PX-478 has been shown in preclinical studies to inhibit hypoxia-inducible factor (HIF)-1 alpha, a protein that controls the transcription of a number of genes whose products are important for tumor growth and survival. In these preclinical studies, PX-478 has produced significant tumor regression and growth delay in multiple models of human cancers, including cancers of the lung, breast, prostate, colon, kidney, pancreas and ovary.
"HIF-1 alpha plays a critical role in the response of tumor cells to low oxygen, a situation seen in tumors where existing blood vessels are insufficient to supply needed oxygen," said Dr. Lynn Kirkpatrick, Chief Scientific Officer of Biomira. "In areas of low oxygen and as tumors grow, they adapt their metabolism due to decreased oxygen and nutrients and attract new blood vessels to bring in more oxygen, a process known as angiogenesis. Both the altered metabolism and angiogenesis are under the control of HIF-1 alpha. Consequently, HIF-1 alpha is a drug target that provides a multi-pronged approach for cancer therapy. We believe that PX-478 will be the first small molecule to enter clinical development that acts directly to lower HIF-1 alpha protein levels."
"With the filing of this IND for PX-478, we are advancing the development of another promising compound," said Dr. Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "Upon clearance of the IND, we intend to initiate a Phase 1 trial for this compound in the third quarter of 2007. We also are on track to advance our other pipeline programs, including initiating another Phase 2 trial for PX-12 and filing an IND for PX-866 by the end of the year. At that point we will have four programs in clinical development, reflecting the diversity and promise of our product pipeline."
About PX-478
PX-478 is a potent inhibitor of HIF-1 alpha, a protein target whose levels are elevated in a wide range of tumors. The protein is a key factor in the response of a cancer cell to hypoxia (lack of oxygen), including the angiogenic cascade that allows tumors to establish new blood vessels essential to their survival and growth. Inhibition of angiogenesis is a validated approach to treating cancer.
In preclinical studies, PX-478 demonstrated antitumor activity when delivered orally and has shown marked tumor regression and growth inhibition, both of which correlated to the HIF-1 alpha levels of the tumor models. These models included ovarian, renal, prostate, colon, pancreatic, lung and breast cancer, representing a large potential market for this product candidate. The ability to combine PX-478 with radiation therapy may further expand the opportunities for this novel compound.
About Biomira
Biomira is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Biomira's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements related to the pre-clinical and clinical development of PX-478, PX-12 and PX-866; the therapeutic and commercial potential of PX-478, PX-12 and PX-866; the filing of an investigational new drug application for PX-478 and PX-866 and the timing thereof; the initiation of a Phase 1 trial for PX-478; the initiation of a Phase 2 trial for PX-12; and future clinical development plans. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes", "anticipates", "plans", "expects", "will", "intends", "potential", "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Biomira's current expectations. Forward-looking statements involve risks and uncertainties. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the clinical development of PX-478, PX-12 and PX-866; the therapeutic and commercial potential of PX-478, PX-12 and PX-866; the filing of an investigational new drug application for PX-478 and PX-866 and the timing thereof; the initiation of a Phase 1 trial for PX-478; the initiation of a Phase 2 trial for PX-12; and future clinical development plans. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. Biomira expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
----------------------------------------------
Investor and Media Relations Contact: Stephanie H. Seiler
Ph.D.
Gemini BioProjects LLC
(206) 713-0124
ir@biomira.com
ZHNE 1.42 Zhone Technologies to Report Second Quarter 2007 Financial Results
Jul 3, 2007 8:00:00 AM
Copyright Business Wire 2007
OAKLAND, Calif.--(BUSINESS WIRE)--
Zhone Technologies, Inc. (NASDAQ: ZHNE), a global provider of advanced communications equipment and a leader in VoIP, IPTV, and Ethernet over both copper and fiber access lines, today announced that the company will report its second quarter 2007 financial results on Tuesday, July 24, 2007, after the close of regular market trading.
Zhone will conduct a conference call and audio webcast to discuss further details of its second quarter 2007 results at approximately 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, July 24, 2007. This call is open to the public by dialing +1 (888) 680-0879 for U.S. callers and +1 (617) 213-4856 for international callers and then entering passcode 31271514. The audio webcast will be simultaneously available on the Investor Relations section of Zhone's website at http://www.zhone.com/about/investors/.
A replay of the conference call will be available for approximately one week after the original call by dialing +1 (888) 286-8010 for U.S. callers and +1 (617) 801-6888 for international callers and then entering passcode 66796909. An audio webcast replay will also be available online at http://www.zhone.com/about/investors/ for approximately one week following the original call.
About Zhone Technologies, Inc.
Zhone Technologies, Inc. (NASDAQ: ZHNE) is a global provider of advanced communications equipment to more than 600 operators in both emerging and established markets. Zhone's market-leading Broadband Loop Carrier equipment enables operators to rapidly deploy revenue-generating access services using their existing infrastructure, while providing a migration path to a cost-efficient, all-IP access network. The company's products address a broad range of applications including residential and business broadband, VoIP, IPTV, and Ethernet over both copper and fiber access lines. Zhone's advanced networking solutions include the Single Line Multi-Service architecture (SLMS(TM)), Multi-Access Line Concentrator (MALC(TM)), Raptor(TM) ATM/IP DSLAMs, GigaMux(TM) Optical Transport Systems and Zhone Management System (ZMS(TM)). www.zhone.com
Source: Zhone Technologies, Inc.
----------------------------------------------
Zhone Technologies
Inc.
Investors:
Susie Choy
+1 510-777-7013
Fax: +1 510-777-7001
investor-relations@zhone.com
or
Pubic Relations:
Tracy Oliver
+1 510-777-7020
Fax : +1 510-777-7001
public-relations@zhone.com
MCEL .63 Protonex Receives Additional Funding to Advance Unmanned Aerial Vehicle Power Systems
Jul 3, 2007 8:00:00 AM
Copyright Business Wire 2007
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--
Protonex Technology Corporation (LSE: PTX), a leading provider of advanced fuel cell power systems for sub-kilowatt portable, remote and mobile applications, today announces that it has received an $800,000 extension to a previously awarded contract with the Air Force Research Laboratory (AFRL) to optimize performance of its unmanned aerial vehicle (UAV) propulsion system, ProCore(TM) UAV. The advanced version of the system is expected to enable longer flight times and increased payload capability of small unmanned aircraft.
Under this extended program, Protonex will increase the power density of the ProCore(TM) UAV fuel cell system. In addition, Protonex will work with subcontractor Millennium Cell, Inc. (NASDAQ: MCEL) to advance the chemical hydride fueling subsystem to increase energy density. These improvements to power and energy density have the potential to deliver fuel cell power systems that can offer up to four times the available energy of batteries of the same size and weight
Recently, Protonex and UAV manufacturer AeroVironment (AV) (NASDAQ:AVAV) successfully flew the AV Puma small unmanned aircraft for nearly five hours powered by a ProCore(TM) UAV hybridized with a battery. Puma's standard propulsion system comes equipped with rechargeable batteries with a listed flight time of 2.5 hours. The nearly five-hour duration of the Puma flight using fuel cell battery hybrid power surpassed the longest previous Puma flight achieved by AeroVironment using any technology.
With the anticipated improvements to the ProCore(TM) UAV system, Protonex expects to achieve flight times of up to ten hours. This capability will address the rapidly growing segment of UAVs designed for surveillance, search and rescue, chemical-biological monitoring and other long-endurance specialty missions.
"Increased endurance and payload capacity are critical capabilities that are not feasible with current battery technology being used in small unmanned aerial vehicles today," stated Dr. Paul Osenar, Chief Technology Officer, Protonex. "We continue to work with leaders in the UAV field to advance this enabling technology, including military end-users and UAV manufacturers, and expect these efforts to yield a significant market opportunity for our fuel cell products."
Notes to Editors
About Protonex Technology Corporation
www.protonex.com
Protonex Technology Corporation develops and manufactures compact, lightweight and high-performance fuel cell systems for portable power applications in the ten to 1000-watt range. The Company's fuel cell systems are designed to meet the needs of military and original equipment manufacturer (OEM) customers for off-grid applications underserved by existing technologies by providing customizable, stand-alone portable power solutions and systems that may be hybridized with existing power technologies. The Company is based in Southborough, Massachusetts.
About Millennium Cell
www.millenniumcell.com
Millennium Cell is a leader in the development of hydrogen battery technology used to power portable applications. Through its proprietary Hydrogen on Demand(R) fuel cartridges and PowerSkin(TM) fuel cell modules, the Company provides increased energy density resulting in longer runtime and lighter weight in a compact space. The Company is working with market partners to meet the demand for a better battery in the military, medical, industrial and consumer electronics markets.
This announcement includes statements which are, or may be deemed to be, "forward-looking statements". All statements other than statements of historical facts included in this announcement, including, without limitation, those regarding Protonex' financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to Protonex' products and services) are forward-looking statements. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Protonex to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. These factors include but are not limited to those described in the Admission Document issued in connection with the Placing.
Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements in this announcement speak only as at the date of this announcement and are subject to risks relating to future events and other risks, uncertainties and assumptions relation to Protonex' operations, results of operations, growth strategy and liquidity.
Source: Protonex Technology Corporation
----------------------------------------------
Protonex
Scott Pearson
Chief Executive Officer
Jennifer Humiston
Marketing Manager
508-490-9960
or
Brunswick Group LLP
Press and Investor Relations
Paul Scott
Alex Tweed
+44 (0)20 7404 5959
or
Canaccord Adams Limited
Nominated Adviser
Robert Finlay
Tyler Broda
+44 (0)20 7050 6500
SSTR 1.89 Silverstar Holdings Announces Commitment for $9 Million Private Placement of Common Stock
Jul 3, 2007 7:53:00 AM
2007 PrimeNewswire, Inc.
BOCA RATON, Fla., July 3, 2007 (PRIME NEWSWIRE) -- Silverstar Holdings, Ltd. (Nasdaq:SSTR) today announced that it has received the binding commitment for a $9 million private placement of common stock and warrants with institutional investors and management. Silverstar sold a total of 6,206,890 shares at $1.45 per share. Investors will also receive five year warrants to purchase approximately 4,344,826 shares of common stock at $2.10 per share. Clive Kabatznik, CEO, and Michael Levy, Chairman, invested in the deal.
The terms of the definitive agreements require Silverstar to obtain the approval of its shareholders for the issuance of shares above 19.99% of its currently outstanding common stock. The Company has agreed to file a registration statement for the first 19.99% of shares issued, and will schedule a special shareholder meeting to vote on approval of the additional shares and other matters. A second registration statement will be filed once approved.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities mentioned in this release. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act of 1933, as amended. These securities described in this release have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent and effective registration statement covering such securities or an applicable exemption from such registration requirements.
About Silverstar Holdings:
Silverstar Holdings, Ltd. is a publicly traded company (Nasdaq:SSTR), focusing on acquiring controlling positions in high-growth retail-driven and fee-based electronic game businesses that stand to benefit from the economies of scale generated by the Internet and other technology-related platforms. It currently owns Empire Interactive, PLC and Strategy First, Inc.
Empire Interactive is a leading publisher of interactive software. It develops and publishes a varied range of titles for all current platforms in the U.S., Europe, and Asia. Games such as FlatOut, Ford Racing, Big Mutha Truckers and Starsky & Hutch have all enjoyed success across the world. Its budget label is one of the fastest growing in Europe. Further information about Empire Interactive and its products can be found at www.empireinteractive.com.
The Empire Interactive logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3408
The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the company's filings with the Securities and Exchange Commission.
CONTACT: Alliance Advisors, LLC
Alan Sheinwald, President
914-669-0222
asheinwald@allianceadvisors.net
NPSP 4.13 NPS Pharmaceuticals Announces Sale of Two Facilities
Jul 3, 2007 8:00:00 AM
PARSIPPANY, N.J., July 3 /PRNewswire-FirstCall/ -- As part of its effort to restructure and consolidate operations, NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today the sale of its former headquarters in Salt Lake City, Utah to the University of Utah and the closing of the sale of its Mississauga, Ontario pilot manufacturing and laboratory facility to Transglobe Property Management Services LTD. The Ontario, Canada facility will net approximately $4 million as a result of the sale of that facility. The company will receive approximately $21 million from the sale of its Utah facility and associated equipment. NPS recently purchased the Salt Lake City facility for $20 million in order to exit from the long-term lease obligation of the sale-leaseback transaction it had entered in 2006. NPS plans to vacate the Salt Lake facility and additional research laboratories it leases at the MaRS Centre in Toronto and consolidate its operations at a new headquarters location in Bedminster, New Jersey later this year.
Gerard Michel, chief financial officer of NPS, stated: "We are pleased to announce the closing of the sale of our pilot plant facility in Canada and the sale of our Salt Lake City facility. These transactions are an important part of our restructuring program and reflect our focus on increasing the company's operating flexibility and strengthening its financial position."
About NPS Pharmaceuticals
NPS discovers and develops small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development backed by a strong discovery research effort. Additional information is available on the company's website, http://www.npsp.com.
Safe Harbor Statement
Note: Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All information in this press release is as of July 3, 2007 and we undertake no duty to update this information. A more complete description of these risks can be found in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year-ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter-ended March 31, 2007.
SOURCE NPS Pharmaceuticals, Inc.
----------------------------------------------
Brandi Simpson
Sr. Director
Investor Relations of NPS Pharmaceuticals
Inc.
+1-801-883-2397
bsimpson@npsp.com
The Nasdaq Stock Market will close at 1:00pm EST on Tuesday, July 3, 2007. On this date, the system changes list will be disseminated at approximately 12:00pm EST.
http://www.otcbb.com/asp/dailylist_detail.asp?d=07/02/2007&mkt_ctg=OTCBB
The Nasdaq Stock Market will close at 1:00pm EST on Tuesday, July 3, 2007. On this date, the system changes list will be disseminated at approximately 12:00pm EST.
http://www.otcbb.com/asp/dailylist_detail.asp?d=07/02/2007&mkt_ctg=OTCBB
The Nasdaq Stock Market will close at 1:00pm EST on Tuesday, July 3, 2007. On this date, the system changes list will be disseminated at approximately 12:00pm EST.
http://www.otcbb.com/asp/dailylist_detail.asp?d=07/02/2007&mkt_ctg=OTCBB
WAGS MUST be posted BEFORE post #22,100,000
$222.20 in Prize money for picking the time of post #222,222,222... Go to IHUB Milestone Board and cast your prediction NOW!!! Pass it On!! http://www.investorshub.com/boards/board.asp?board_id=1594
$222.20 in Prize money for picking the time of post #222,222,222... Go to IHUB Milestone Board and cast your prediction NOW!!! Pass it On!! http://www.investorshub.com/boards/board.asp?board_id=1594
wag entry >> 8/27/2007 2:05pm
******* CTTJ > CYPW added to ibox ******
CYPW- Cyclone Power Technologies Inc. Reverse Split History
Symbol Split Ratio Date
CTTJ 1:10,000 R/S 07/02/2007
CTTJ 20:1 F/S 10/23/2006
SDAI name change to CTTJ 11/07/2005
NCST 1:5 R/S 10/26/2004
13:42 6/28/2007 PMWI 1-20 R/S ** Public Media Works, Inc. Common Stock PUBM Public Media Works, Inc. New Common Stock
13:42 6/28/2007 NWBT 1-15 R/S **Northwest Biotherapeutics, Inc. Common stock NWBO Northwest Biotherapeutics, Inc. New Common stock
6/28/2007 GMXX 1-2.5 R/S ** GeneMax Corporation Common Stock TPIM TapImmune Inc. Common Stock
SPAB .71 SPACEHAB Reports Successful Hardware Handover
Company to Deliver and Return Critical Components During Upcoming STS-118 Mission
Jun 27, 2007 11:16:00 AM
Copyright Business Wire 2007
HOUSTON--(BUSINESS WIRE)--
SPACEHAB, Incorporated (NASDAQ:SPAB), a leading provider of commercial space services, today announced the successful delivery of its Logistics Single Module (LSM), manifested for flight on the upcoming STS-118 mission, to the Kennedy Space Center (KSC) in Cape Canaveral, Florida from the SPACEHAB Payload Processing Facility (SPPF), also located at the Cape.
Last week, the Company's External Stowage Platform 3 (ESP3), scheduled to be deployed from the shuttle's cargo bay and permanently attached to the International Space Station (ISS) during STS-118, was also successfully turned over to NASA for final integration with the space shuttle Endeavor. The ESP3, successor to the highly acclaimed ESP2, which was attached to the ISS during the STS-114 mission in 2005, was designed to provide another permanent spare parts storage facility for the growing orbiting laboratory and its crew members.
During Endeavor's STS-118 mission, currently scheduled for August 9, 2007, SPACEHAB's pressurized logistics module will ferry approximately 3,200 pounds of cargo for delivery to the space station, including several major equipment spare parts, food and clothing for visiting crews, as well as various experiments.
"The final turnover of our flight hardware for this complex ISS assembly and logistics mission is the result of years of work and a myriad of testing, analysis, and training," explains Pete Paceley, Vice President, SPACEHAB Flight Services. "We are extremely proud of our team and the continued dedication they have exhibited in providing our NASA and Lockheed Martin customers with SPACEHAB's signature professionalism and customer service."
Returning home with the shuttle crew, SPACEHAB's LSM will bring back to Earth approximately 3,000 pounds of cargo including excess equipment and a high priority Department of Defense payload known as the "MISSE PEC." This suitcase-sized test bed was attached to the outside of the ISS during STS-121 in July 2006 and contained approximately 875 specimens of various materials, representing 40 different investigators including NASA centers, military space organizations, aerospace contractors and manufacturers. The containers exposed hundreds of potential space construction materials and solar cells to the harsh environment of space. Upon STS-118's return, the equipment will undergo post flight analysis, providing investigators with data to design a stronger, more durable spacecraft.
"The complexities of sending cargo and science to space is a very specialized capability for which SPACEHAB professionals are highly proficient, recognized in the industry, and represent the exact skills needed in the Company's new direction of on-orbit manufacturing and processing," said SPACEHAB CEO, Thomas B. Pickens, III. "It is an absolute delight to work with this highly trained team that has had such a vital role in helping deliver permanent hardware and cargo to the ISS, a designated U.S. National Laboratory, in the upcoming STS-118 mission."
About SPACEHAB, Incorporated
Incorporated in 1984, SPACEHAB (www.spacehab.com) is a leading provider of commercial space products and services to NASA, international space agencies and universities, Department of Defense, and private customers worldwide. The Company offers end-to-end space access solutions, space systems development, mission integration and pre-launch processing facilities and services, and large-scale government program support services.
The statements in this document may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the company's Securities & Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.
Source: SPACEHAB, Inc.
----------------------------------------------
SPACEHAB
Inc.
Houston
Corporate Marketing and Communications
Eva-Marie deCardenas
713-558-5071
edecardenas@spacehab.com
SPAB .71 SPACEHAB Reports Successful Hardware Handover
Company to Deliver and Return Critical Components During Upcoming STS-118 Mission
Jun 27, 2007 11:16:00 AM
Copyright Business Wire 2007
HOUSTON--(BUSINESS WIRE)--
SPACEHAB, Incorporated (NASDAQ:SPAB), a leading provider of commercial space services, today announced the successful delivery of its Logistics Single Module (LSM), manifested for flight on the upcoming STS-118 mission, to the Kennedy Space Center (KSC) in Cape Canaveral, Florida from the SPACEHAB Payload Processing Facility (SPPF), also located at the Cape.
Last week, the Company's External Stowage Platform 3 (ESP3), scheduled to be deployed from the shuttle's cargo bay and permanently attached to the International Space Station (ISS) during STS-118, was also successfully turned over to NASA for final integration with the space shuttle Endeavor. The ESP3, successor to the highly acclaimed ESP2, which was attached to the ISS during the STS-114 mission in 2005, was designed to provide another permanent spare parts storage facility for the growing orbiting laboratory and its crew members.
During Endeavor's STS-118 mission, currently scheduled for August 9, 2007, SPACEHAB's pressurized logistics module will ferry approximately 3,200 pounds of cargo for delivery to the space station, including several major equipment spare parts, food and clothing for visiting crews, as well as various experiments.
"The final turnover of our flight hardware for this complex ISS assembly and logistics mission is the result of years of work and a myriad of testing, analysis, and training," explains Pete Paceley, Vice President, SPACEHAB Flight Services. "We are extremely proud of our team and the continued dedication they have exhibited in providing our NASA and Lockheed Martin customers with SPACEHAB's signature professionalism and customer service."
Returning home with the shuttle crew, SPACEHAB's LSM will bring back to Earth approximately 3,000 pounds of cargo including excess equipment and a high priority Department of Defense payload known as the "MISSE PEC." This suitcase-sized test bed was attached to the outside of the ISS during STS-121 in July 2006 and contained approximately 875 specimens of various materials, representing 40 different investigators including NASA centers, military space organizations, aerospace contractors and manufacturers. The containers exposed hundreds of potential space construction materials and solar cells to the harsh environment of space. Upon STS-118's return, the equipment will undergo post flight analysis, providing investigators with data to design a stronger, more durable spacecraft.
"The complexities of sending cargo and science to space is a very specialized capability for which SPACEHAB professionals are highly proficient, recognized in the industry, and represent the exact skills needed in the Company's new direction of on-orbit manufacturing and processing," said SPACEHAB CEO, Thomas B. Pickens, III. "It is an absolute delight to work with this highly trained team that has had such a vital role in helping deliver permanent hardware and cargo to the ISS, a designated U.S. National Laboratory, in the upcoming STS-118 mission."
About SPACEHAB, Incorporated
Incorporated in 1984, SPACEHAB (www.spacehab.com) is a leading provider of commercial space products and services to NASA, international space agencies and universities, Department of Defense, and private customers worldwide. The Company offers end-to-end space access solutions, space systems development, mission integration and pre-launch processing facilities and services, and large-scale government program support services.
The statements in this document may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the company's Securities & Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.
Source: SPACEHAB, Inc.
----------------------------------------------
SPACEHAB
Inc.
Houston
Corporate Marketing and Communications
Eva-Marie deCardenas
713-558-5071
edecardenas@spacehab.com